[Asia Economy Reporter Chunhee Lee] GC Cell announced on the 9th that it has appointed James Park, former Vice President of Samsung Biologics, as the new CEO through a board meeting.
James Park, the newly appointed CEO, majored in Chemical Engineering at the University of California, Davis (UC Davis) and earned a master's degree in Industrial Engineering from Columbia University. He is recognized as a global pharmaceutical and bio expert, having worked at major pharmaceutical companies such as Merck and Bristol-Myers Squibb (BMS), and serving as Vice President of the Global Sales Center (CBO) at Samsung Biologics from 2015 until recently.
At BMS, he participated in over 100 drug process development and quality control (CMC) audits from the preclinical stage to commercialization, overseeing business development activities including technology introduction, export, and mergers and acquisitions (M&A). At Samsung Biologics, as CBO, he successfully closed deals worth approximately $5.5 billion (about 7 trillion KRW) over seven years.
A GC Cell official stated, "The newly appointed CEO Park is an expert with comprehensive understanding and experience across the pharmaceutical and bio business value chain, from new drug development to commercial production and sales. We expect him to lead GC Cell to grow as a global leader in the cell therapy field." James Park is scheduled to be officially appointed through the upcoming regular shareholders' meeting and board meeting next month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
